PAD-Focused Medtechs Eye Golden Period In Growing Silver Market
Improving the patient’s QoL and preventing disease progression, and with it the threat of critical limb ischemia and amputation, dominate peripheral artery disease management, but emerging technologies and the aging population are set to boost a percutaneous transluminal angioplasty market that is already worth $730 million in the US alone.
You may also be interested in...
At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.
The market for peripheral vascular interventions and diagnostics is poised for significant growth in the years ahead, driven by an aging population and the growing incidence of peripheral vascular disease, along with new technological developments such as drug-eluting balloons, which are inching closer to regulatory approval in the US.
An increasing proportion of patients are presenting to cath labs with calcified plaque, and emerging cardiovascular interventions are driving the demand for calcium debulking technologies that are more benign than conventional atherectomy or balloon angioplasty. Shockwave Medical’s novel platform for debulking calcified plaque in vessels is based on lithotripsy, the use of mechanical energy to fracture kidney stones; the start-up believes it has a technology that’s specific for calcium and benign to healthy tissue.